MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: In vivo studies with positron emission tomography

European Journal of Clinical Pharmacology

Volumn 52, Issue 2, 1997, Pages 121-128

  Bergstrom M ^a   Westerberg, G ^a   Nemeth G ^b   Traut, M ^b   Gross, G ^b   Greger, G ^b   Muller Peltzer H ^b   Safer, A ^b   Eckernas S A ^c   Grahner A ^c   Langstrom B ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Knoll AG   (Germany)

^c PMC Contract Research AB   (Sweden)

Author keywords

Esuprone; antidepressive drugs; MAO A; moclobemide; Positron emission tomography

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CARBON 11; ESUPRONE; HARMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRAIN TOMOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG UPTAKE; ENZYME BINDING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; BENZAMIDES; BRAIN; CARBON RADIOISOTOPES; COUMARINS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HARMINE; HUMANS; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PLACEBOS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 8244255002     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050260     Document Type: Article

References (27)

1. Bench CJ, Price GW, Lammertsma AA, Cremer JC, Luthra SK. et al (1991) Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 40: 169-175
2. Fowler JS, Volkow ND, Logan J, Schluer DJ, et al (1993) Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327. Neurology 43: 1984-1992
3. 11C)deprenyl and dynamic positron emission tomography. J Cereb Blood Flow Metab 11: 545 556
4. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538 544
5. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71 76
6. Nordstrom AL, Farde L, Halldin C (1993) High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl) 110 (3): 365 367
7. 11C-labelled suicide inactivators and PET. Science 235: 481-485
8. 11C-detiterium-deprenyl in temporal lobe epilepsy. Epilepsia 36: 712 721
9. Frost JJ, Mayberg HS, Fisher RS, Douglass KH, Dannals RF, Links JU, Wilson AA, Ravert TH, Rosenbaum AE, Snyder SH, Wagner HN (1988) Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol 23: 231 237
10. MacGregor RR, Fowler JS, Wolf AP, Halldin C, Längs from B (1988) Synthesis of suicide inhibitors of monoamine oxidase: carbon-11 labeled clorgyline, L- and D-deprenyl. J Lab Comp Radiopharm 25: 1 11
11. 11C]-brolaromine, a potential tracer for measuring MAO-A activity with PET. (abstract) Eur J Nucl Med 21: 876
12. 76Br]-brofaromine for PET studies of MAO-A activity. Proceedings of the Eleventh International Symposium on Radiopharmaceutical Chemistry, Vancouver, Canada, August 1995, pp 232-233
13. Hirata M, Magata Y, Ohmomo Y, Saji H, Murakami K, Takagaki T, Yamamura N, Tanaka C, Konishi J, Yokoyama A (1995) Evaluation of radioiodonated iodoclorgyline as a SPECT radiopharmaceutical for MAO-A of the brain. Nucl Med Biol 22: 175-180
14. 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey. Nucl Med Biol (in press)
15. 11C-Harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol (in press)
16. Thase ME, Rush AJ (1995) Treatment-resistant depression. In: Bloom EE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 1081-1097
17. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF (1988) Antidepressant specificity in atypical depression. Arch Gen Psychiatry 45: 129 137
18. Robinson DS, Kurtz NM (1987) Monoamine oxidase inhibiting drugs: pharmacologic and therapeutic issues. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 1297-1304
19. Laux G, Votz H-P, Möller H-J (1995) Newer and older monoumine oxidase inhibitors. A comparative profile. CNS Drugs 3: 145-158
20. Thase ME, Trivedi MH, Rush AJ (1995) MAOIs in the contemporary treatment of depression. Review. Neuropsycho-pharmacology 12: 185 219
21. Cesura AM, Pletscher A (1992) The new generation of monoamine oxidase inhibitors. Prog Drug Res 38: 171 297
22. Freeman H (1993) Moclobemide Lancet 342: 1528-1532
23. Kops ER, Herzog H, Schmid A, Holte S, Feinendegen LE (1990) Performance characteristics of an eight-ring whole body PET scanner. J Comput Assist Tomogr 14: 437-445
24. Holte S, Eriksson L, Dahlbom M (1989) A preliminary evaluation of the Scanditronix PC2048-15B brain scanner. Eur J Nucl Med 15: 719-721
25. Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphic evaluation of blood-to-brain transfer constants from multipletime uptake data. J Cereb Blood Flow Metab 3: 1-7
26. 3H)Harman binding experiments. 1. A reversible and selective radioligand for monoamine oxidase subtype A in the CNS of the rat. J Neurochem 56: 490-499
27. 3H)harmine binding and monoamine oxidase subtypes A and B activity in marmoset and rat. J Neurochem 56: 500-508